So far, 25 general practices across the Healthy North Coast footprint have expressed interest in receiving allocations of the Novavax COVID-19 vaccine.
The Therapeutic Goods Administration provisionally approved Novavax for use in Australia on 20 January, 2022.
Novavax will be available for people aged 18 years and over who have not received their primary course vaccinations. It is not authorised for use as a booster dose.
Interested practices will receive an initial ongoing allocation up to 200 doses a fortnight of Novavax. Practices may request an increase in allocation after the first administration week.
Sites approved for the administration of Novavax through the EOI process are expected to be able to place orders for the new product in the COVID-19 Vaccine Administration System (CVAS) in staged tranches starting from February 2022.
The initial EOI deadline of 26 January was only for those practices wanting delivery of Novavax in the first window – from mid to late February.
Novavax will also be included in the standing ‘expression of interest’ for all general practices wanting to expand their participation in the vaccine delivery program. General practices still assessing the need in their area can be onboarded at any time. Contact your Primary Health Coordinator for information and assistance.
Before receiving vaccine doses, sites will be required to complete the Novavax Site Readiness Declaration in the CVAS.
Practices are reminded they should not book appointments until:
- the Australian Technical Advisory Group on Immunisation has confirmed Novavax’s inclusion in the program
- confirmation of delivery dates for the new vaccine.